Avodart is prescribed to shrink an enlarged prostate in men with a condition called benign prostatic hyperplasia. It works by lowering amounts of the hormone responsible for prostate growth (dihydrotestosterone). Avodart reduces urinary blockage and improves urine flow.
Avodart is prescribed to treat prostate enlargement, a condition that is medically known as benign prostatic hyperplasia, or BPH.
The prostate is a chestnut-shaped gland that is part of the male reproductive system. It produces a liquid that forms part of the semen. This gland completely encloses the upper part of the urethra, the tube through which urine flows out of the bladder. Many men over age 50 suffer from a benign (noncancerous) enlargement of the prostate. The enlarged gland squeezes the urethra, obstructing the normal flow of urine. Resulting problems may include difficulty in starting urination, weak flow of urine, and the need to urinate urgently or more frequently. Sometimes surgical removal of the prostate is necessary.
By shrinking the enlarged prostate, Avodart may alleviate the various urinary symptoms, making surgery unnecessary. You will need to see your doctor for periodic examinations to assess your response to treatment. It may take several months before you notice an improvement in symptoms.
Avodart side effects that you should report to your health care professional or doctor as soon as possible:
- Enlarged Breasts In Males;
- Ejaculation Problems;
- Decreased Sex Drive;
- Breast Tenderness;
- Decrease In The Amount Of Ejaculate;
- Decreased Interest In Sex;
- Sexual Problems;
Avodart may also cause breast enlargement and/or tenderness. If any of these effects persist or worsen, contact your doctor or pharmacist promptly.
An allergic reaction to this drug is unlikely, but seek immediate medical attention if it occurs. Symptoms of an allergic reaction include:
- Trouble Breathing;
For ADULT MEN
Take one 0.5-mg capsule once a day. The capsule should be swallowed whole.
Avodart has not been evaluated for use in children under 18.